Market Research Logo

Liposarcoma - Pipeline Review, H2 2016

Liposarcoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liposarcoma – Pipeline Review, H2 2016, provides an overview of the Liposarcoma (Oncology) pipeline landscape.

Liposarcoma is a malignant tumor of fatty tissue. Symptoms include noticeable lump or swelling, pain, weight loss and abdominal pain. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liposarcoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liposarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liposarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Liposarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 10, 3 and 2 respectively.Liposarcoma.

Liposarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liposarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Liposarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liposarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liposarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Liposarcoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liposarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Liposarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Liposarcoma Overview
Therapeutics Development
Pipeline Products for Liposarcoma - Overview
Liposarcoma - Therapeutics under Development by Companies
Liposarcoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Liposarcoma - Products under Development by Companies
Liposarcoma - Companies Involved in Therapeutics Development
Adaptimmune Therapeutics Plc
Amgen Inc
Cellceutix Corp
Eli Lilly and Company
Horizon Pharma Plc
Immune Design Corp
Karyopharm Therapeutics Inc
Merck & Co Inc
Mirati Therapeutics Inc
Novartis AG
Pfizer Inc
Liposarcoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abemaciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMB-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-3377794 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HDM-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon gamma-1b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kevetrin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pazopanib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ribociclib succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sitravatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vimo-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Liposarcoma - Dormant Projects
Liposarcoma - Discontinued Products
Liposarcoma - Product Development Milestones
Featured News & Press Releases
Nov 09, 2016: Adaptimmune Announces Removal of Partial Clinical Hold in Myxoid/Round Cell Liposarcoma
Aug 03, 2016: Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma
Aug 03, 2016: Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR T-cell Therapy in Myxoid Round Cell Liposarcoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Liposarcoma, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Liposarcoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
Liposarcoma - Pipeline by Amgen Inc, H2 2016
Liposarcoma - Pipeline by Cellceutix Corp, H2 2016
Liposarcoma - Pipeline by Eli Lilly and Company, H2 2016
Liposarcoma - Pipeline by Horizon Pharma Plc, H2 2016
Liposarcoma - Pipeline by Immune Design Corp, H2 2016
Liposarcoma - Pipeline by Karyopharm Therapeutics Inc, H2 2016
Liposarcoma - Pipeline by Merck & Co Inc, H2 2016
Liposarcoma - Pipeline by Mirati Therapeutics Inc, H2 2016
Liposarcoma - Pipeline by Novartis AG, H2 2016
Liposarcoma - Pipeline by Pfizer Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Liposarcoma - Dormant Projects, H2 2016
Liposarcoma - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Liposarcoma, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report